Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis COMFORT-I

por Miller, Carole B., Komrokji, Rami S., Mesa, Ruben A., Sun, William, Montgomery, Michael, Verstovsek, Srdan
Publicado 2017

Efficacy of COVID-19 Convalescent Plasma Based on Antibody Concentration

por Cain, Wesley V, Sill, Anne M, Solipuram, Vinod, Weiss, John J, Miller, Carole B, Jelsma, Peter F
Publicado 2022

Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey

por Mesa, Ruben, Miller, Carole B., Thyne, Maureen, Mangan, James, Goldberger, Sara, Fazal, Salman, Ma, Xiaomei, Wilson, Wendy, Paranagama, Dilan C., Dubinski, David G., Boyle, John, Mascarenhas, John O.
Publicado 2016

Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findin...

por Mesa, Ruben A., Miller, Carole B., Thyne, Maureen, Mangan, James, Goldberger, Sara, Fazal, Salman, Ma, Xiaomei, Wilson, Wendy, Paranagama, Dilan C., Dubinski, David G., Naim, Ahmad, Parasuraman, Shreekant, Boyle, John, Mascarenhas, John O.
Publicado 2016

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

por Verstovsek, Srdan, Mesa, Ruben A., Gotlib, Jason, Gupta, Vikas, DiPersio, John F., Catalano, John V., Deininger, Michael W. N., Miller, Carole B., Silver, Richard T., Talpaz, Moshe, Winton, Elliott F., Harvey, Jimmie H., Arcasoy, Murat O., Hexner, Elizabeth O., Lyons, Roger M., Paquette, Ronald, Raza, Azra, Jones, Mark, Kornacki, Deanna, Sun, Kang, Kantarjian, Hagop
Publicado 2017